Translated from our German original by AI. The German text was researched, written, and edited by the Psychedelia Foundation team and remains the authoritative version.
Alcohol dependence is one of the most common and most consequential addictive disorders worldwide. Despite the therapies available, many of those affected do not manage to reduce their drinking lastingly or to avoid relapse over the long term. Interest is correspondingly high in new compounds that do not only treat withdrawal symptoms but make deeper changes to pathologically learned behavior patterns possible.
A recent preclinical study now identifies oxa-noribogaine as a promising candidate for exactly this approach. The substance is chemically derived from ibogaine, a psychedelic natural compound that occurs among other places in the African plant Tabernanthe iboga and has been studied for decades for its addiction-treatment properties. Unlike that parent compound, however, oxa-noribogaine appears not to carry two central drawbacks of ibogaine: as far as is currently known it does not act psychedelically, and in preclinical work it does not show the cardiovascular risks that fundamentally complicate the use of ibogaine.
Advantages over ibogaine
Earlier pharmacological work describes oxa-noribogaine as a mechanistically distinct molecule that could retain the addiction-treatment properties of ibogaine without producing its typical psychedelic or oneirogenic effects. Instead of activating serotonergic psychedelic mechanisms, oxa-noribogaine acts above all through kappa-opioid receptors, and in doing so shows a pharmacological profile clearly different from that of the classical psychedelics.
The second decisive difference concerns safety. Ibogaine has been associated for years with potentially serious cardiac arrhythmias. Experimental work has shown that ibogaine can prolong the electrical repolarization of human heart muscle cells and thereby raise the risk of dangerous arrhythmias. For oxa-noribogaine, preclinical studies have so far produced a different picture: in human cardiomyocytes, oxa-iboga compounds showed none of the proarrhythmic effects that are detectable with ibogaine and noribogaine. Researchers state explicitly that this molecule does not carry the “proarrhythmic side effects” of the parent substances.
The alcohol study now published likewise reports that no detectable motor or cardiac burden was observed under oxa-noribogaine.
Learning from negative consequences
At the center of the new study were rat models of alcohol dependence. They showed that oxa-noribogaine does not simply suppress alcohol consumption pharmacologically. Rather, the substance apparently strengthens a learning process: in the study, the animals learned more strongly from the negative consequences of their drinking behavior. It is precisely this finding that is of particular interest from an addiction medicine perspective. Dependence is often characterized by harmful behavior being continued despite negative consequences. The results suggest that oxa-noribogaine could specifically influence this disrupted processing of learning.
Lasting reduction in drinking and relapse behavior
After the substance was administered, the researchers observed not only a clear reduction in alcohol intake but also a sustained reduction in relapse-like drinking behavior. In direct comparison, oxa-noribogaine at least matched the efficacy of ibogaine and exceeded it in individual models. Notably, these effects were not confined to a single experimental model: they were reproduced in several translational models, in genetically different laboratory animals, and at research sites independent of one another.
Changes in central brain circuits
Alongside the behavioral effects, the researchers recorded temporary changes in the activity of prefrontal brain regions. They also found longer-lasting changes in glutamatergic signaling after aversion-related learning, as well as a normalization of neurotrophic signaling pathways in cortico-striatal networks. These findings support the hypothesis that oxa-noribogaine does not simply suppress the craving for alcohol in the short term but may help to reorganize disease-relevant neural circuits lastingly.
A possible paradigm shift?
The study identifies oxa-noribogaine not only as a potential new candidate for the treatment of alcohol dependence. It also provides indications that therapeutically relevant neuroplasticity may not necessarily have to be tied to a psychedelic experience.
Should these preclinical results be confirmed in clinical studies in humans, oxa-noribogaine could belong to a new generation of addiction-treatment compounds, inspired by psychedelic natural substances but without their hallucinations and without the cardiac safety problem known so far for ibogaine.
Sources:
Meinhardt M, Skorodumov I, Walter F, Akan M, Buchborn T, LE Prieult Y, Urban M, Spanagel R, von Ammon L, Hopf C, Kalinichenko L, Mueller C, Winter C, Hadar R, Gül AZ, Massuda B, Hildebrandt M, Domi E, Keshishian A, Ciccocioppo R, Sames D, Havel V, Woods L, Beeson A. (2026), Oxa-noribogaine reduces alcohol drinking through aversion learning and by altering glutamatergic activity in the mPFC. Res Sq [Preprint], 31: rs.3.rs-9103509.
